Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa

NCT01653743 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01653743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01653743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2014
Enrollment
81 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anovulation, hypothalamic-pituitary dysfunction, oligo-ovulation, polycystic ovarian syndrome